The Cell and Gene Therapy Catapult: consortium formed for improvement of manufacturing processes

The Cell and Gene Therapy Catapult (London, UK), with the support of Innovate UK (Swindon, UK), have formed a consortium of over 20 organizations to advance technology development in the fields of cell and gene therapy.

The consortium will work to assess the applications of new and already used process analytical technologies in the context of the cell and gene therapy industry. By working together and sharing data between them, they want to improve monitoring of manufacturing processes, allowing a reduction in batch failures and manufacturing costs.

“The industry needs to make a giant leap in terms of analytical capability and the dynamic use of information to control and improve processes, product and costs. The coming together of these leaders in the field is a very important first step towards achieving this,” commented Matthew Durdy, Chief Executive Officer at The Cell and Gene Therapy Catapult.

The consortium brings together a variety of organizations. It includes pharmaceutical companies, technology providers, therapy developers and charities, such as GlaxoSmithKline (Brentford, UK), Bio-Techne (MI, USA), Eppendorf (Stevenage, UK) and Anthony Nolan (London, UK).

“By sharing knowledge and data, the consortium members will be able to reap potentially huge benefits that could lead to more efficient processes in this vital field,” explained Nicholas Medcalf, Deputy Challenge Director – Medicines Manufacturing at Innovate UK. “The Cell and Gene Therapy Catapult – supported by Innovate UK – is demonstrating its fantastic convening power in harnessing these leading industry players for the greater good of UK enterprise and innovation.”

 Link:www.regmednet.com/the-cell-and-gene-therapy-catapult-consortium-formed-for-improvement-of-manufacturing-processes/